Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc filed a Form 6-K to disclose daily activity under its ongoing share buyback programme. On 11 July 2025 the company repurchased 486,127 ordinary shares (31 ¼ p nominal) on the London Stock Exchange at prices between 1,405.50 p and 1,454.50 p, producing a volume-weighted average price of 1,420.61 p. The shares will be held in treasury.
Including this tranche, GSK has bought back 12,239,897 shares since the non-discretionary agreement with Merrill Lynch International commenced on 4 June 2025. Treasury stock now stands at 230,374,280 shares, representing 5.64 % of total voting rights. The company’s outstanding share count, excluding treasury shares, is 4,085,009,777.
The disclosure also provides granular trade data for regulatory transparency in accordance with the UK FCA’s Disclosure Guidance and Transparency Rules.
GSK plc reported the purchase of 335,358 ordinary shares on 10 July 2025 under its ongoing buy-back programme executed by Merrill Lynch International. Prices ranged from 1,430.50p to 1,462.00p with a volume-weighted average price of 1,449.95p.
Since the programme’s launch on 4 June 2025, GSK has repurchased 11,753,770 shares. Following the latest purchase the company now holds 229,888,153 shares in treasury, representing 5.63 % of total voting rights, leaving 4,085,493,697 shares outstanding (ex-treasury).
The filing consists mainly of the aggregate data above and a detailed schedule of individual trades executed on the London Stock Exchange. No new guidance, financial results or material corporate actions were disclosed.
GSK plc (GSK) filed a Form 6-K detailing activity under its authorised share repurchase programme.
- Date of purchase: 8 July 2025
- Shares bought: 480,940 ordinary shares of 31 ¼ pence each
- Price range: 1,388.50 p – 1,416.50 p; VWAP: 1,405.17 p
- Broker: Merrill Lynch International, acting under a non-discretionary agreement dated 4 June 2025
- Programme progress: Since 4 June 2025 the company has repurchased 10,944,632 shares
- Treasury position: Treasury shares now total 229,079,015, representing 5.61 % of voting rights
- Shares in issue (ex-treasury): 4,086,302,835; this is also the new denominator for FCA DTR 5 calculations
The filing includes a complete schedule of trades executed on the London Stock Exchange (XLON). No trades occurred on CBOE CHIX or BATE on the stated date.
Contact details for media and investor relations representatives are provided. A standard cautionary note reminds investors of forward-looking statement risks.
GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.
Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.
No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.
GSK plc filed a Form 6-K disclosing the latest execution under its ongoing share repurchase programme.
- Shares repurchased: 491,972 ordinary shares on 03 July 2025.
- Price range: 1,380.50 p – 1,411.00 p; VWAP: 1,396.15 p.
- Programme history: Since the non-discretionary agreement with Merrill Lynch International on 04 June 2025, the company has bought back 9,493,915 shares.
- Treasury position: After this purchase GSK holds 227,628,298 shares in treasury, equal to 5.57 % of total voting rights.
- Shares outstanding (ex-treasury): 4,087,741,901.
- The repurchase volume on 03 July represents around 0.012 % of shares in issue, while cumulative June–July purchases equal roughly 0.23 %.
The filing provides the standard denominator for Disclosure Guidance and Transparency Rule (DTR) calculations and lists each individual trade executed on the London Stock Exchange. No other financial, operational or strategic information is included.